«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第3期

页码:

348-351,365

栏目:

综述

出版日期:

2016-01-05

文章信息/Info

Title:

New progress of high-dose intensive statin administration in patients prior to percutaneous coronary intervention

作者:

孙佳玉; 刘广忠; 李为民

(哈尔滨医科大学附属第一临床医学院心内科,黑龙江 哈尔滨 150001)

Author(s):

SUN Jia-yu;  LIU Guang-zhong;  LI Wei-min

(Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)

关键词:

强化他汀; 经皮冠状动脉介入治疗; 安全性

Keywords:

intensive statins;  percutaneous coronary intervention;  safety

分类号:

R514.4

DOI:

-

文献标识码:

A

摘要:

他汀类药物可减少围手术期心肌损伤、弥漫性心肌坏死、心肌梗死和无复流现象发生，可能与其降低炎症反应、改善内皮功能、抑制血栓形成等多效性作用有关。此外，强化他汀治疗可减少经皮冠状动脉介入（percutaneous coronary intervention，PCI）术后发生对比剂肾病(contrast-induced nephropathy，CIN)的风险，可能是全因死亡率及心血管死亡率减低的非心源性机制。目前PCI术前强化他汀治疗成为临床医生关注的热点，本文将对PCI术前强化他汀的获益、作用机制以及安全性的相关研究新进展做一综述。

Abstract:

Statins exert anti-inflammatory effects, modulate endothelial function, reduce low-grade inflammation and decrease thrombotic diathesis. Together the non-LDL cholesterol-lowering effects of statins are called pleiotropic effects. Statins may reduce cardiac injury, diffuse cardiac necrosis, myocardial infarction and no-reflow phenomenon, which are probably related to the pleiotropic effects of statins. A decreased risk of contrast-induced nephropathy (CIN) post-PCI might be an extracardiac mechanism that contributes to the reduction of all-cause and cardiovascular disease mortality. In this article we will review the evidence supporting the administration of high-dose statins in patients undergoing percutaneous coronary intervention and we will also attempt to highlight the possible mechanisms of action and safety of intensive statins.

参考文献/References

[1]Murphy SA,Cannon CP,Wiviott SD,et al.Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial[J].J Am Coll Cardiol,2009,54(25):2358-2362.
[2]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352(14):1425-1435.
[3]Amarenco P,Bogousslavsky J,Callahan A 3rd,et al.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355(6):549-559.
[4]Nissen SE.Effect of intensive lipid lowering on progression of coronary atherosclerosis:evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering(REVERSAL)trial[J].Am J Cardiol,2005,96(5):61-68.
[5]Nissen SE,Nicholls SJ,Sipahi I,et al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J].JAMA,2006,295(13):1556-1165.
[6]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].Circulation,2011,124(23):e574- e651.
[7]霍 勇，葛均波，韩雅玲，等.急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志,2014,22(1):4-6.
[8]Briguori C,Visconti G,Focaccio A,et al.Novel approaches for preventing or limiting events(Naples)impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J].J Am Coll Cardiol,2009,54(23):2157-2163.
[9]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial[J].J Am Coll Cardiol, 2007,49(12):1272-1278.
[10]Di Sciascio G1,Patti G,Pasceri V,et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty)Randomized Trial[J].J Am Coll Cardiol,2009,54(6):558-565.
[11]Navarese EP,Kowalewski M,Andreotti F,et al.Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Am J Cardiol,2014,113(10):1753-1764.
[12]Tentzeris I,Rohla M,Jarai R,et al.Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes[J].Am J Cardiol,2014,113(7):1099-1104.
[13]Yun KH,Jeong MH,Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome［J］. Int J Cardiol, 2009, 137(3):246-251.
[14]Ray KK, Cannon CP, McCabe CH,et al.PROVE IT-TIMI 22 Investigators.Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes:results from the PROVE IT-TIMI 22 trial[J].J Am Coll Cardiol,2005,46(8):1405-1410.
[15]Gibson CM,Pride YB,Hochberg CP,et al.TIMI Study Group.Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome.PCI-PROVE IT:A PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22)Substudy[J].J Am Coll Cardiol,2009,54(24):2290-2295.
[16]de Lemos JA,Blazing MA,Wiviott SD,et al.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial[J].JAMA,2004,292(11):1307-1316.
[17]Prasad K.Do statins have a role in reduction/prevention of post-PCI restenosis?[J].Cardiovasc Ther,2013,31(1):12-26.
[18]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial[J].JAMA,2001,285(13):1711-1718.
[19]Li XD,Yang YJ,Hao YC,et al.Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention:a metaanalysis[J].Chin Med J(Engl),2013,126(9):1755-1760.
[20]Leoncini M,Toso A,Maioli M,et al.Early high-dose rosuvastatin for contrastinduced Nephropathy prevention in acute coronary syndrome.Results from the PRATO-ACS study(Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome)[J].J Am Coll Cardiol,2014,63(1):71-79.
[21]Han Y,Zhu G,Han L,et al.Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease[J].J Am Coll Cardiol,2014,63(1):62-70.
[22]Mikhailidis DP,Athyros VG.Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI[J].Nat Rev Nephrol,2014,10(1):8-9.
[23]Quintavalle C,Fiore D,De Micco F,et al.Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury[J].Circulation,2012,126(25):3008-3016.
[24]Li W1,Fu X,Wang Y,et al.Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention[J].Cardiology,2012,122(3):195-202.
[25]Patti G,Ricottini E,Nusca A,et al.Short-term,high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention(from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy]trial)[J].Am J Cardiol,2011,108(1):1-7.
[26]Desai CS,Martin SS,Blumenthal RS.Non-cardiovascular effects associated with statins[J].BMJ,2014,349:g3743.
[27]2014年中国胆固醇教育计划血脂异常防治建议专家组,中华心血管病杂志编辑委员会,血脂与动脉粥样硬化循证工作组,等.2014年中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病杂志, 2014,42(8):633-636.

备注/Memo

备注/Memo:

收稿日期：2015-03-04.
通讯作者：李为民，教授，主要从事心血管介入治疗研究 Email：liweimin_2009@163.com
作者简介：孙佳玉，硕士生 Email：sunjiayu_23@163.com

常用功能

更新日期/Last Update: 2016-01-07